首页|孟鲁司特联合布地奈德治疗小儿哮喘的临床疗效及安全性研究

孟鲁司特联合布地奈德治疗小儿哮喘的临床疗效及安全性研究

扫码查看
目的 探讨孟鲁司特联合布地奈德治疗小儿哮喘的临床疗效及安全性.方法 选取2016年5月~2017年2月本院收治的70例小儿哮喘患儿作为研究对象,按照随机原则分为A组和B组,各35例.A组采用单一布地奈德治疗,B组给予孟鲁司特联合布地奈德治疗.比较2组哮喘临床疗效;体温恢复正常时间、喘息消失时间、实验室指标正常时间、胸片正常时间;干预前后患儿炎性因子、肺部功能指标;不良反应发生情况.结果 B组哮喘临床疗效高于A组(P<0.05);B组体温恢复正常时间、喘息消失时间、实验室指标正常时间、胸片正常时间短于A组(P<0.05);干预前2组炎性因子、肺部功能指标相近;干预后B组炎性因子、肺部功能指标优于A组(P<0.05).2组治疗过程未见明显不良反应发生.结论 孟鲁司特联合布地奈德治疗小儿哮喘的临床疗效及安全性高,可改善患儿症状,促使症状在短时间内消退,降低炎性因子,改善肺功能,无明显不良反应,安全有效.
Clinical efficacy and safety of montelukast combined with budesonide in the treatment of children
Objective To investigate the clinical efficacy and safety of montelukast combined with budesonide in the treatment of children with asthma. Methods 70 cases of children with asthma were randomly divided into group A and group B, included 35 cases in each group. Group A was treated with single budesonide and Group B was given montelukast combined with budesonide. The clinical efficacy of two groups of asthma was compared, the body temperature returned to normal time, the time of wheezing disappeared, the normal time of the laboratory index, the normal time of the chest radiograph, the inflammatory factors and the lung function indexes and the side effects. Results The clinical curative effect of group B was higher than that of group A(P<0.05); Body temperature in group B returned to normal time, the time of wheezing disappeared, the normal time of laboratory index was shorter than that of group A(P<0.05); Inflammatory factors and lung function were similar. After intervention, the inflammatory factors and lung function of group B were better than those of group A(P<0.05). There were no obvious side effects in the two groups. Conclusion The clinical efficacy and safety of montelukast combined with budesonide in the treatment of children with asthma can improve the symptoms of children, cause the symptoms to recite in a short time, reduce the inflammatory factors, improve lung function, no obvious adverse reactions, safety effective.

montelukastbudesonidepediatric asthmaclinical efficacysafety

穆璐、郁峰

展开 >

湖州市中心医院 儿科,浙江 湖州 313000

孟鲁司特 布地奈德 小儿哮喘 临床疗效 安全性

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(9)
  • 16
  • 10